Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

New Cystic Fibrosis Test Aids in Parent and Newborn Screening

By LabMedica International staff writers
Posted on 17 Sep 2009
A new cystic fibrosis (CF) test screens potential parents to determine if they are carriers of CF-causing gene mutations and in confirmatory diagnostic testing in newborns and children.

The xTAG Cystic Fibrosis 39 kit (v2) detects 39 CF-causing gene mutations, including the 23 CF transmembrane conductance regulator (CFTR) gene mutations and four variants (polymorphisms) recommended by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG), as well as 16 additional CFTR gene mutations from human blood specimens. More...
The xTAG kit is flexible, offering physicians the ability to select the CFTR gene mutations for which they want to test, up to the entire panel of 39 CFTR gene mutations.

This flexibility is intended to allow laboratories to avoid having to use different platforms for various testing purposes, thus saving time and resources. Additionally--similar to the first-generation xTAG CF test (v1)--the new xTAG Cystic Fibrosis 39 kit v2 does not require reflex testing; all results are revealed and available for analysis at each run, if necessary. The protocol for testing has been streamlined to make the process faster and easy to use. The xTAG Cystic Fibrosis 39 kit (v2) is a product of Luminex (Austin, TX, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"The first FDA-cleared molecular diagnostic test for cystic fibrosis demonstrated Luminex's leadership in innovative CF testing. With this improved product, we focused on our customers' need to have a faster and easier to use IVD-cleared test with broad genetic mutation coverage,” said Patrick J. Balthrop, President and CEO of Luminex. "The xTAG Cystic Fibrosis 39 kit v2 gives doctors the ability to quickly, accurately and effectively screen potential parents for CF gene mutations and diagnose the disease early, which will assist in improving the health and quality of life of people with CF around the world.”

CF is a chronic inherited genetic disease in which the body produces thick, sticky mucus that can clog the lungs and affect the digestive system, and can have debilitating and potentially life-threatening consequences. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, of which over 1,500 have been identified to date. Late diagnosis of the disease is associated with chronic lung infections and compromised growth, whereas early detection and treatment has been shown to reduce therapeutic needs, lower rates of complications, and increase life expectancy.

Related Links:

Luminex




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.